These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 31648846)

  • 41. Hepatitis and pneumonitis during adalimumab therapy in Crohn disease: mind the histoplasmosis!
    Pinheiro Bdo V; Delgado Ade A; Chebli JM
    Arq Gastroenterol; 2014; 51(1):73-6. PubMed ID: 24760069
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Simultaneous development of sarcoidosis and cutaneous vasculitis in a patient with refractory Crohn's disease during infliximab therapy.
    Numakura T; Tamada T; Nara M; Muramatsu S; Murakami K; Kikuchi T; Kobayashi M; Muroi M; Okazaki T; Takagi S; Eishi Y; Ichinose M
    BMC Pulm Med; 2016 Feb; 16():30. PubMed ID: 26864464
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Probable diffuse retinopathy caused by adalimumab in a patient with Crohn's disease.
    Marticorena-Álvarez P; Chaparro M; Pérez-Casas A; Muriel-Herrero A; Gisbert JP
    J Crohns Colitis; 2012 Oct; 6(9):950-3. PubMed ID: 22537636
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Meningococcemia without meningitis in Japan.
    Horino T; Kato T; Sato F; Sakamoto M; Nakazawa Y; Yoshida M; Onodera S; Kohda M; Matsuo K; Ishiji T; Takahashi H; Watanabe H
    Intern Med; 2008; 47(17):1543-7. PubMed ID: 18758132
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pulmonary actinomycosis coexisting with intestinal tuberculosis as a complication of adalimumab treatment for Crohn's disease.
    Aleric I; Katalinic D; Vcev A; Brinar M
    Acta Gastroenterol Belg; 2017; 80(4):544-546. PubMed ID: 29560655
    [No Abstract]   [Full Text] [Related]  

  • 46. Pulmonary cryptococcosis in a patient with Crohn's disease treated with prednisone, azathioprine and adalimumab: exposure to chicken manure as a source of contamination.
    Fraison JB; Guilpain P; Schiffmann A; Veyrac M; Le Moing V; Rispail P; Le Quellec A
    J Crohns Colitis; 2013 Feb; 7(1):e11-4. PubMed ID: 22647638
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in paediatric patients with Crohn's disease: a post hoc analysis.
    Hyams JS; Dubinsky M; Rosh J; Ruemmele FM; Eichner SF; Maa JF; Lazar A; Alperovich G; Mostafa NM; Robinson AM
    Aliment Pharmacol Ther; 2019 Jan; 49(2):155-164. PubMed ID: 30506693
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rapid diagnosis of acute meningococcal infections by needle aspiration or biopsy of skin lesions.
    van Deuren M; van Dijke BJ; Koopman RJ; Horrevorts AM; Meis JF; Santman FW; van der Meer JW
    BMJ; 1993 May; 306(6887):1229-32. PubMed ID: 7684633
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Fever with a rash caused by chronic meningococcemia].
    de Jonge JC; Koop K; Bousema M; Nuboer R
    Ned Tijdschr Geneeskd; 2015; 159():A8103. PubMed ID: 25850448
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Management of recurrent cutaneous abscesses during therapy with infliximab.
    De Simone C; Murri R; Maiorino A; Venier A; Caldarola G
    Clin Ther; 2011 Dec; 33(12):1993-6. PubMed ID: 22088412
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents.
    Kim ES; Song GA; Cho KB; Park KS; Kim KO; Jang BI; Kim EY; Jeon SW; Lee HS; Yang CH; Lee YK; Lee DW; Kim SK; Kim TO; Lee J; Kim HW; Jee SR; Park SJ; Kim HJ
    World J Gastroenterol; 2015 Mar; 21(11):3308-16. PubMed ID: 25805938
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Guillain-Barrè syndrome after treatment with human anti-tumor necrosis factorα (adalimumab) in a Crohn's disease patient: case report and literature review.
    Cesarini M; Angelucci E; Foglietta T; Vernia P
    J Crohns Colitis; 2011 Dec; 5(6):619-22. PubMed ID: 22115384
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Oligosymptomatic alimentary tract perforation in course of Crohn's disease in patient treated with anti-TNF alfa antibodies].
    Jałocha Ł; Wojtuń S; Wojtkowiak M; Błaszak A; Dyrla P; Gil J
    Pol Merkur Lekarski; 2009 May; 26(155):491-2. PubMed ID: 19606707
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adalimumab-Induced Cutaneous Lupus Erythematosus in a 16-Year-Old Girl with Juvenile Idiopathic Arthritis.
    West ES; Nanda K; Ofodile O; Rutledge J; Brandling-Bennett HA
    Pediatr Dermatol; 2015; 32(4):e140-4. PubMed ID: 25845414
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A pain in the joints.
    Peters R; Virani F; Haddadin Y; Baldowska H
    BMJ Case Rep; 2015 Feb; 2015():. PubMed ID: 25694633
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Adalimumab for the treatment of Crohn's disease - consensus paper of the Working Group "chronic inflammatory bowel diseases" of the Austrian Society for Gastroenterology and Hepatology].
    Reinisch W; Haas T; Kaser A; Petritsch W; Vogelsang H; Feichtenschlager T; Novacek G; Siebert F; Tilg H; Knoflach P
    Z Gastroenterol; 2009 Apr; 47(4):372-80. PubMed ID: 19358065
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Adalimumab for the treatment of adult Crohn's disease--update of a consensus report by the Working Group Inflammatory Bowel Disease of the Austrian Society of Gastroenterology and Hepatology].
    Novacek G; Haas T; Knoflach P; Petritsch W; Tilg H; Vogelsang H; Reinisch W
    Z Gastroenterol; 2013 Sep; 51(9):1101-9. PubMed ID: 23996653
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies.
    Panaccione R; Löfberg R; Rutgeerts P; Sandborn WJ; Schreiber S; Berg S; Maa JF; Petersson J; Robinson AM; Colombel JF
    J Crohns Colitis; 2019 May; 13(6):725-734. PubMed ID: 30753371
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients.
    Baumgart DC; Grittner U; Steingräber A; Azzaro M; Philipp S
    Inflamm Bowel Dis; 2011 Dec; 17(12):2512-20. PubMed ID: 21351201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.